Ingredient Library
Reference articles on clascoterone terminology, how it compares with other approaches, and what the published literature does and does not say.
CB-03-01, cortexolone 17α-propionate, clascoterone and Winlevi all refer to the same molecule at different stages of its life. Here is the naming map.
RU58841 is frequently discussed online as a topical anti-androgen. The mechanism is similar to clascoterone's; the evidence base and regulatory status are not.
Same molecule, two very different delivery systems. The vehicle determines where the active goes and how it feels.
Hair count endpoints, vehicle controls and dose response — how to read clascoterone's trial results without overstating them.
Topical clascoterone has been studied in more than 1,465 patients in Phase III. Here is what the safety data actually reported — and what remains unknown.
One works systemically upstream of DHT production, the other locally at the receptor. The difference explains almost everything about their respective safety conversations.
The 5% concentration is the most frequently referenced strength in clascoterone scalp research. Here is what the concentration means in practice.
These two topicals are often framed as competitors. They are not: one addresses the cause of miniaturisation, the other extends the growth phase. Here is the mechanistic difference in full.
Clascoterone is the first topical androgen receptor antagonist studied for androgenetic alopecia. Here is what the science actually shows — mechanism, trial data, dosing and realistic expectations.